Tarsus Pharmaceuticals, Inc.

NasdaqGS:TARS Voorraadrapport

Marktkapitalisatie: US$1.8b

Tarsus Pharmaceuticals Toekomstige groei

Future criteriumcontroles 5/6

De verwachting is dat Tarsus Pharmaceuticals de winst en omzet met respectievelijk 67.2% en 38% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 67.1% per jaar.

Belangrijke informatie

67.2%

Groei van de winst

67.1%

Groei van de winst per aandeel

Pharmaceuticals winstgroei23.9%
Inkomstengroei38.0%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Good

Laatst bijgewerkt15 Nov 2024

Recente toekomstige groei-updates

US$65.33 - That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results

Nov 16
US$65.33 - That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results

Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

May 11
Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

Recent updates

US$65.33 - That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results

Nov 16
US$65.33 - That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results

Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41%

Nov 07
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41%

Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money

Nov 05
Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable

Sep 05
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable

Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment

Aug 20

With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For

Jun 26
With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For

Following Up On Tarsus Pharmaceuticals

May 28

Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

May 11
Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name

Mar 08

Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic

Mar 03
Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 01
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?

Feb 28
Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?

New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Nov 12
New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates

Aug 16
What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates

Winst- en omzetgroeiprognoses

NasdaqGS:TARS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026503101N/AN/A4
12/31/2025311-71N/AN/A7
12/31/2024174-121N/AN/A7
9/30/2024130-134-102-100N/A
6/30/202483-150-129-124N/A
3/31/202443-148-139-133N/A
12/31/202317-136-123-117N/A
9/30/202314-108-95-89N/A
6/30/202313-91-77-75N/A
3/31/202328-65-56-56N/A
12/31/202226-62-50-49N/A
9/30/202216-63-51-50N/A
6/30/202217-56-25-25N/A
3/31/202224-4400N/A
12/31/202157-1434N/A
9/30/202157-1066N/A
6/30/202155-5-8-8N/A
3/31/202133-15-32-31N/A
12/31/2020N/A-27-22-21N/A
9/30/2020N/A-17-12-12N/A
6/30/2020N/A-7-6-6N/A
3/31/2020N/A-5-5-5N/A
12/31/2019N/A-5-4-4N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat TARS de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat TARS de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat TARS binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van TARS ( 38% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van TARS ( 38% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van TARS naar verwachting over 3 jaar hoog zal zijn


Ontdek groeibedrijven